Assessment of inflammatory markers in patients with ulcerative colitis treated with tofacitinib

Assessment of inflammatory markers in patients with ulcerative colitis treated with tofacitinib - Inflammatory markers in UC

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON40572

Enrollment

Registered

2013-10-28

Start date

2013-11-05

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ulcerative colitis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. patients (*18 years) with ulcerative colitis with an indication to start Tofacitinib within the OCTAVE induction study (METC2012_072) and responding to this therapy 2. patients (*18 years) with ulcerative colitis with an indication to start Tofacitinib within the Open Label study (METC_075), after having been defined as a non-responder within the participation in the OCTAVE Induction study (METC2012_072)

Exclusion criteria

Exclusion criteria: subjects without previous treatment for UC

Design outcomes

Primary

Measure	Time frame
inflammatory infiltrate, transcription of inflammatory genes, phosphorylation of Jak/Stat proteins.	—

Secondary

Measure	Time frame
none	—

Countries

Netherlands

Outcome results